

Please detach before submitting to a pharmacy - tear here

PATIENT INFORMATION **PRESCRIBER INFORMATION**

Please complete the following or send patient demographic sheet

Patient Name _____
 Address _____
 Address 2 _____
 City, State, Zip _____
 Home Phone _____ Alternate Phone _____
 DOB _____ Last Four of SS# _____ Gender _____
 Language Preference: English Spanish Other _____

Prescriber's Name _____
 DEA _____
 NPI _____
 Group/Hospital _____
 Address _____
 City, State, ZIP _____
 Phone _____ Fax _____
 Contact Person _____ Phone _____

INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number: _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)

Diagnosis - Please include diagnosis name with ICD-10 code

M06.9 Rheumatoid arthritis, unspecified
 M08.00 Unspecified juvenile rheumatoid arthritis of unspecified site
 M08.3 Juvenile rheumatoid polyarthritis (seronegative)
 M45.9 Ankylosing spondylitis of unspecified sites in spine
 L40.59 Other Psoriatic Arthropathy
 Other Diagnosis: ICD-10 Code _____ Description _____
 Date of diagnosis _____
 Has a TB test been performed? Yes No
 Does the patient have an active infection? Yes No
 Start Date _____ Review Date _____

Additional Information Therapy: New Reauthorization Restart
 Weight _____ kg/lbs Height _____ cm/in
 Allergies _____
 Lab Data _____
 Prior Therapies _____
 Concomitant Medications _____
 Additional Comments _____
 Injection Training Required: Yes No

PRESCRIPTION INFORMATION

Medication	Strength	Dose & Directions	Qty/Refills
<input type="checkbox"/> Actemra	<input type="checkbox"/> 80 mg/4 mL Vial <input type="checkbox"/> 200 mg/10 mL Vial <input type="checkbox"/> 400 mg/20 mL Vial	<input type="checkbox"/> Induction Dose: Infuse 4 mg/kg IV every 4 weeks. <input type="checkbox"/> Maintenance Dose: Infuse 8 mg/kg IV every 4 weeks (please record patient weight at the top of this form). <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Actemra	<input type="checkbox"/> 162 mg/0.9 mL prefilled syringe <input type="checkbox"/> 162 mg/0.9 mL ACTPen Autoinjector	<input type="checkbox"/> For patients weighing <100 kg: Inject 162 mg SC every other week, followed by an increase to every week based on clinical response. <input type="checkbox"/> For patients weighing ≥ 100 kg: Inject 162 mg SC every week.	Quantity: _____ Refills: _____
<input type="checkbox"/> Amjevita™	<input type="checkbox"/> 20 mg/0.4 mL Prefilled Syringe (citrate-free) <input type="checkbox"/> 40 mg/0.8 mL Prefilled Syringe (citrate-free) <input type="checkbox"/> 40 mg/0.8 mL Prefilled SureClick® autoinjector (citrate-free)	<input type="checkbox"/> Inject 40 mg SC every OTHER week. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Avsola	100 mg Vial	<input type="checkbox"/> Induction Dose: Infuse _____ mg/kg IV at weeks 0, 2 and 6. <input type="checkbox"/> Maintenance Dose: Infuse _____ mg/kg IV every 6 weeks. <input type="checkbox"/> Maintenance Dose: Infuse _____ mg/kg IV every 8 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ # of 100 mg vial Refills: _____
<input type="checkbox"/> Benlysta	<input type="checkbox"/> 120 mg Vial <input type="checkbox"/> 400 mg Vial	<input type="checkbox"/> Induction Dose: 10 mg/kg/dose IV infused over 1 hour every 2 weeks for the first 3 doses (0 refills). <input type="checkbox"/> Maintenance Dose: Inject 10 mg/kg/dose IV once every 4 weeks.	Quantity: _____ Refills: _____
<input type="checkbox"/> Benlysta	<input type="checkbox"/> 200 mg/mL Prefilled Syringe <input type="checkbox"/> 200 mg/mL Autoinjector	<input type="checkbox"/> Maintenance Dose: Inject 200 mg SC once every week.	Quantity: _____ Refills: _____
<input type="checkbox"/> Cimzia	<input type="checkbox"/> 200 mg/mL Starter Kit (6 prefilled syringes)	Induction Dose: Inject 400mg SC at weeks 0, 2 and 4.	Quantity: 1 Kit Refills: 0
<input type="checkbox"/> Cimzia	<input type="checkbox"/> 200 mg/mL Vial Kit <input type="checkbox"/> 200 mg/mL Prefilled Syringe	<input type="checkbox"/> Maintenance Dose: Inject 200 mg SC every OTHER week. <input type="checkbox"/> Maintenance Dose: Inject 400 mg SC every four weeks. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Cosentyx	<input type="checkbox"/> Sensoready® pen 150 mg/mL injection <input type="checkbox"/> Prefilled syringe 150 mg/mL injection	Psoriatic Arthritis with Coexistent Moderate to Severe Plaque Psoriasis <input type="checkbox"/> Loading Dose: Inject 300 mg (two injections) SC at weeks 0, 1, 2, 3 and 4 (10 pens/syringes, 0 refills). <input type="checkbox"/> Maintenance Dose: Inject 300 mg (two injections) SC every 4 weeks. Other Psoriatic Arthritis or Ankylosing Spondylitis <input type="checkbox"/> With Loading Dose: Inject 150 mg (one injection) SC at weeks 0, 1, 2, 3 and 4, and then every 4 weeks thereafter (5 pens/syringes, 0 refills). <input type="checkbox"/> Without Loading Dose: Inject 150 mg (one injection) SC every 4 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____

*Prescriber Authorization: I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: Patient Office Other _____ Date _____ Needs by Date _____
 Product Substitution permitted Dispense as Written
 Prescriber's Signature _____ Date _____ Supervising Physician Signature: _____ Date _____
 Electronic or digital signatures not accepted.

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone. This form is not a valid prescription in Arizona.

Specialty Pharmacy Enrollment Form

This form is not a valid prescription in Arizona

Please detach before submitting to a pharmacy - tear here

PATIENT INFORMATION **PRESCRIBER INFORMATION**

Please complete the following or send patient demographic sheet

Patient Name _____
 Address _____
 Address 2 _____
 City, State, Zip _____
 Home Phone _____ Alternate Phone _____
 DOB _____ Last Four of SS# _____ Gender _____
 Language Preference: English Spanish Other _____

Prescriber's Name _____
 DEA _____
 NPI _____
 Group/Hospital _____
 Address _____
 City, State, ZIP _____
 Phone _____ Fax _____
 Contact Person _____ Phone _____

INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number: _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)

Diagnosis – Please include diagnosis name with ICD-10 code

M06.9 Rheumatoid arthritis, unspecified
 M08.00 Unspecified juvenile rheumatoid arthritis of unspecified site
 M08.3 Juvenile rheumatoid polyarthritis (seronegative)
 M45.9 Ankylosing spondylitis of unspecified sites in spine
 L40.59 Other Psoriatic Arthropathy
 Other Diagnosis: ICD-10 Code _____ Description _____
 Date of diagnosis _____
 Has a TB test been performed? Yes No
 Does the patient have an active infection? Yes No
 Start Date _____ Review Date _____

Additional Information Therapy: New Reauthorization Restart

Weight _____ kg/lbs Height _____ cm/in
 Allergies _____
 Lab Data _____
 Prior Therapies _____
 Concomitant Medications _____
 Additional Comments _____
Injection Training Required: Yes No

PRESCRIPTION INFORMATION

<input type="checkbox"/> Enbrel	<input type="checkbox"/> 25 mg/0.5 mL prefilled syringe <input type="checkbox"/> 25mg/0.5ml single-dose vial <input type="checkbox"/> 50 mg/mL Sureclick™ Autoinjector <input type="checkbox"/> 50 mg/mL prefilled syringe <input type="checkbox"/> 50 mg/mL Enbrel Mini™ prefilled cartridge for use with the <u>AutoTouch™ reusable autoinjector only</u> (prescriber MUST supply). Avella/Briova does not order the autoinjector.	<input type="checkbox"/> Inject 25 mg SC TWICE a week (72 – 96 hours apart). <input type="checkbox"/> Inject 50 mg SC ONCE a week. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Humira	<input type="checkbox"/> 10 mg/0.1 mL Prefilled Syringe (citrate-free) <input type="checkbox"/> 20 mg/0.2 mL Prefilled Syringe (citrate-free) <input type="checkbox"/> 40 mg/0.4 mL Prefilled Syringe (citrate-free) <input type="checkbox"/> 40 mg/0.4 mL Pen (citrate-free) <input type="checkbox"/> 10 mg/0.2 mL Prefilled Syringe <input type="checkbox"/> 20 mg/0.4 mL Prefilled Syringe <input type="checkbox"/> 40 mg/0.8 mL Prefilled Syringe <input type="checkbox"/> 40 mg/0.8 mL Pen	<input type="checkbox"/> Inject 40 mg SC every OTHER week. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Inflectra	100 mg Vial	<input type="checkbox"/> Induction Dose: Infuse _____ mg/kg IV at weeks 0, 2 and 6. <input type="checkbox"/> Maintenance Dose: Infuse _____ mg/kg IV every 6 weeks. <input type="checkbox"/> Maintenance Dose: Infuse _____ mg/kg IV every 8 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ # of 100 mg vial Refills: _____
<input type="checkbox"/> Kevzara	<input type="checkbox"/> 200 mg/1.14 mL Prefilled Syringe <input type="checkbox"/> 150 mg/1.14 mL Prefilled Syringe <input type="checkbox"/> 200 mg/1.14 mL Prefilled Pen <input type="checkbox"/> 150 mg/1.14 mL Prefilled Pen	<input type="checkbox"/> Inject 200 mg SC once every two weeks. <input type="checkbox"/> Inject 150 mg SC once every two weeks.	Quantity: _____ Refills: _____
<input type="checkbox"/> Olumiant	<input type="checkbox"/> 1 mg Tablet <input type="checkbox"/> 2 mg Tablet	<input type="checkbox"/> Take 2 mg PO once daily. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Orencia	250 mg vial	<input type="checkbox"/> Infuse _____ mg IV at weeks 0, 2 and 4, then every 4 weeks thereafter (please record patient weight at the top of the form). <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Orencia	<input type="checkbox"/> ClickJect Autoinjector 125 mg/mL pack of 4 <input type="checkbox"/> 125 mg Prefilled Syringe <input type="checkbox"/> 875 mg/0.7ml Prefilled Syringe <input type="checkbox"/> 50 mg/0.4ml Prefilled Syringe	<input type="checkbox"/> Inject 125 mg SC every week. <input type="checkbox"/> Inject 875 mg SC every week. <input type="checkbox"/> Inject 50 mg SC every week. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: Patient Office Other _____ Date _____ Needs by Date _____

Product Substitution permitted Dispense as Written

Prescriber's Signature _____ Date _____ Supervising Physician Signature: _____ Date _____

Electronic or digital signatures not accepted.

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone. This form is not a valid prescription in Arizona.

Specialty Pharmacy Enrollment Form

This form is not a valid prescription in Arizona

Please detach before submitting to a pharmacy - tear here

PATIENT INFORMATION **PRESCRIBER INFORMATION**

Please complete the following or send patient demographic sheet

Patient Name _____
 Address _____
 Address 2 _____
 City, State, Zip _____
 Home Phone _____ Alternate Phone _____
 DOB _____ Last Four of SS# _____ Gender _____
 Language Preference: English Spanish Other _____

Prescriber's Name _____
 DEA _____
 NPI _____
 Group/Hospital _____
 Address _____
 City, State, ZIP _____
 Phone _____ Fax _____
 Contact Person _____ Phone _____

INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number: _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)

Diagnosis – Please include diagnosis name with ICD-10 code

M06.9 Rheumatoid arthritis, unspecified
 M08.00 Unspecified juvenile rheumatoid arthritis of unspecified site
 M08.3 Juvenile rheumatoid polyarthritis (seronegative)
 M45.9 Ankylosing spondylitis of unspecified sites in spine
 L40.59 Other Psoriatic Arthropathy
 Other Diagnosis: ICD-10 Code _____ Description _____
 Date of diagnosis _____
 Has a TB test been performed? Yes No
 Does the patient have an active infection? Yes No
Start Date _____ **Review Date** _____

Additional Information Therapy: New Reauthorization Restart

Weight _____ kg/lbs Height _____ cm/in
 Allergies _____
 Lab Data _____
 Prior Therapies _____
 Concomitant Medications _____
 Additional Comments _____
Injection Training Required: Yes No

PRESCRIPTION INFORMATION

<input type="checkbox"/> Otezla	Titration Starter Pack	Day 1: 10 mg PO in the morning. Day 2: 10 mg PO in the morning and 10 mg PO in the evening. Day 3: 10 mg PO in the morning and 20 mg PO in the evening. Day 4: 20 mg PO in the morning and 20 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 6 and thereafter: 30 mg PO twice daily.	Quantity: 1 Pack Refills: 0
<input type="checkbox"/> Otezla	30 mg Tablet	<input type="checkbox"/> Maintenance Dose: 30 mg PO twice daily. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Remicade	100 mg Vial	<input type="checkbox"/> Induction Dose: Infuse _____ mg/kg IV at weeks 0, 2 and 6. <input type="checkbox"/> Maintenance Dose: Infuse _____ mg/kg IV every 6 weeks. <input type="checkbox"/> Maintenance Dose: Infuse _____ mg/kg IV every 8 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ # of 100 mg vial Refills: _____
<input type="checkbox"/> Renflexis	100 mg Vial	<input type="checkbox"/> Induction Dose: Infuse _____ mg/kg IV at weeks 0, 2 and 6. <input type="checkbox"/> Maintenance Dose: Infuse _____ mg/kg IV every 6 weeks. <input type="checkbox"/> Maintenance Dose: Infuse _____ mg/kg IV every 8 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ # of 100 mg vial Refills: _____
<input type="checkbox"/> Rinvoq	15 mg	<input type="checkbox"/> Take one 15 mg tablet PO once daily. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Simponi Aria	50 mg/4 mL in a single use vial	Infuse 2 mg/kg IV over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter (please record patient weight in section above).	Quantity: _____ # of 50 mg vial Refills: _____
<input type="checkbox"/> Simponi	<input type="checkbox"/> 50 mg/0.5 mL Prefilled SmartJect® Autoinjector <input type="checkbox"/> 50 mg/0.5 mL Prefilled Syringe	<input type="checkbox"/> Inject 50 mg SC once a month. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Skyrizi	<input type="checkbox"/> 150 mg/mL prefilled syringe <input type="checkbox"/> 150 mg/mL prefilled pen	<input type="checkbox"/> Psoriatic Arthritis Induction Dose: Inject 150 mg SC at Weeks 0 and 4, then maintenance dosing (0 refills). <input type="checkbox"/> Psoriatic Arthritis Maintenance Dose: Inject 150mg SC every 12 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Stelara	<input type="checkbox"/> 45 mg/0.5 mL Prefilled Syringe <input type="checkbox"/> 90 mg/mL Prefilled Syringe	<input type="checkbox"/> Induction Dose: For patients weighing ≤100 kg (220 lbs): Inject 45 mg SC initially and 4 weeks later, (2 syringes, 0 refills). <input type="checkbox"/> Induction Dose: For patients weighing >100 kg (220 lbs): Inject 90 mg SC initially and 4 weeks later, (2 syringes, 0 refills). <input type="checkbox"/> Maintenance Dose: Inject 1 syringe SC every 12 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: Patient Office Other _____ Date _____ Needs by Date _____

Product Substitution permitted Dispense as Written

Prescriber's Signature _____ Date _____ Supervising Physician Signature: _____ Date _____

Electronic or digital signatures not accepted.

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone. This form is not a valid prescription in Arizona.

Specialty Pharmacy Enrollment Form

This form is not a valid prescription in Arizona

✂ Please detach before submitting to a pharmacy - tear here

Please complete the following or send patient demographic sheet

Patient Name _____
 Address _____
 Address 2 _____
 City, State, Zip _____
 Home Phone _____ Alternate Phone _____
 DOB _____ Last Four of SS# _____ Gender _____
 Language Preference: English Spanish Other _____

Prescriber's Name _____
 DEA _____
 NPI _____
 Group/Hospital _____
 Address _____
 City, State, ZIP _____
 Phone _____ Fax _____
 Contact Person _____ Phone _____

Prior Authorization Reference number: _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)

Diagnosis – Please include diagnosis name with ICD-10 code

M06.9 Rheumatoid arthritis, unspecified
 M08.00 Unspecified juvenile rheumatoid arthritis of unspecified site
 M08.3 Juvenile rheumatoid polyarthritis (seronegative)
 M45.9 Ankylosing spondylitis of unspecified sites in spine
 L40.59 Other Psoriatic Arthropathy
 Other Diagnosis: ICD-10 Code _____ Description _____
 Date of diagnosis _____
 Has a TB test been performed? Yes No
 Does the patient have an active infection? Yes No
Start Date _____ **Review Date** _____

Additional Information Therapy: New Reauthorization Restart

Weight _____ kg/lbs Height _____ cm/in
 Allergies _____
 Lab Data _____
 Prior Therapies _____
 Concomitant Medications _____
 Additional Comments _____
Injection Training Required: Yes No

PRESCRIPTION INFORMATION

<input type="checkbox"/> Taltz	<input type="checkbox"/> 80 mg Single Dose Autoinjector <input type="checkbox"/> 80 mg Single Dose Prefilled Syringe	Ankylosing Spondylitis/Psoriatic Arthritis Dosing: <input type="checkbox"/> Starting Dose: Inject SC two 80 mg injections on Day 1. (2 injections, 0 refills). <input type="checkbox"/> Maintenance Dose: Inject SC one 80 mg injection every 4 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Tremfya*	<input type="checkbox"/> 100 mg/mL prefilled syringe <input type="checkbox"/> 100 mg/ml One-Press Injector	<input type="checkbox"/> Induction Dose: Inject 100mg SC at week 0 and week 4 (2 syringes/pens, 0 refills). <input type="checkbox"/> Maintenance Dose: Inject 100mg SC once every 8 weeks.	Quantity: _____ Refills: _____
<input type="checkbox"/> Xeljanz	<input type="checkbox"/> 5 mg Tablet <input type="checkbox"/> 11 mg Extended-Release Tablet	<input type="checkbox"/> Take one 5 mg tablet PO twice daily. <input type="checkbox"/> Take one 11 mg tablet PO once daily. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Other	_____	_____	Quantity: _____ Refills: _____

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: Patient Office Other _____ Date _____ Needs by Date _____

Product Substitution permitted Dispense as Written

Prescriber's Signature _____ Date _____ Supervising Physician Signature: _____ Date _____

Electronic or digital signatures not accepted.

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone. This form is not a valid prescription in Arizona.